Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for back pain: drug 608 trial targets ankylosing spondylitis

NCT ID NCT07261644

First seen Jan 04, 2026 · Last updated May 24, 2026 · Updated 20 times

Summary

This study tests a new drug called 608 in 500 adults with active ankylosing spondylitis, a type of arthritis that causes back pain and stiffness. Participants will receive either 608 or a placebo to see if the drug improves symptoms like pain and mobility. The goal is to find a better treatment option for people who haven't responded well to standard anti-inflammatory drugs.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANKYLOSING SPONDYLITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Site 01

    RECRUITING

    Beijing, Beijing Municipality, 100730, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.